journal article·2020-05

The entry of nanoparticles into solid tumours

Shrey Sindhwani, Abdullah Muhammad Syed, Jessica Ngai, Benjamin R. Kingston, Laura Maiorino, Jeremy Rothschild, Presley MacMillan, Yuwei Zhang, Netra Unni Rajesh, Tran Hoang, Jamie L. Y. Wu, Stefan Wilhelm, Anton Zilman, Suresh Gadde, Andrew Sulaiman, Ben Ouyang, Zachary Lin, Lisheng Wang, Mikala Egeblad, Warren C. W. Chan

Nature Materials· Volume 19· Issue 5
Publisher page

Abstract

The concept of nanoparticle transport through gaps between endothelial cells (inter-endothelial gaps) in the tumour blood vessel is a central paradigm in cancer nanomedicine. The size of these gaps was found to be up to 2,000 nm. This justified the development of nanoparticles to treat solid tumours as their size is small enough to extravasate and access the tumour microenvironment. Here we show that these inter-endothelial gaps are not responsible for the transport of nanoparticles into solid tumours. Instead, we found that up to 97% of nanoparticles enter tumours using an active process through endothelial cells. This result is derived from analysis of four different mouse models, three different types of human tumours, mathematical simulation and modelling, and two different types of imaging techniques. These results challenge our current rationale for developing cancer nanomedicine and suggest that understanding these active pathways will unlock strategies to enhance tumour accumulation.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Gold and Silver Nanoparticles Synthesis and Applications · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (53)

Show source-provided references
1. Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016).10.1038/natrevmats.2016.14 ↗
2. Jain, R. K. Transport of molecules, particles, and cells in solid tumors. Annu. Rev. Biomed. Eng. 1, 241–263 (1999).10.1146/annurev.bioeng.1.1.241 ↗
3. Hobbs, S. K. et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl Acad. Sci. USA 95, 4607–4612 (1998).10.1073/pnas.95.8.4607 ↗
4. Jain, R. K. & Stylianopoulos, T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7, 653–664 (2010).10.1038/nrclinonc.2010.139 ↗
5. Hashizume, H. et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156, 1363–1380 (2000).10.1016/S0002-9440(10)65006-7 ↗
6. Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751–760 (2007).10.1038/nnano.2007.387 ↗
7. Gerlowski, L. E. & Jain, R. K. Microvascular permeability of normal and neoplastic tissues. Microvasc. Res. 31, 288–305 (1986).10.1016/0026-2862(86)90018-X ↗
8. Matsumura, Y. & Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387–6392 (1986).
9. Nichols, J. W. & Bae, Y. H. EPR: evidence and fallacy. J. Control. Release 190, 451–464 (2014).10.1016/j.jconrel.2014.03.057 ↗
10. Danhier, F. To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? J. Control. Release 244, 108–121 (2016).10.1016/j.jconrel.2016.11.015 ↗
11. Kim, S. M., Faix, P. H. & Schnitzer, J. E. Overcoming key biological barriers to cancer drug delivery and efficacy. J. Control. Release 267, 15–30 (2017).10.1016/j.jconrel.2017.09.016 ↗
12. Nakamura, Y., Mochida, A., Choyke, P. L. & Kobayashi, H. Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer? Bioconjug. Chem. 27, 2225–2238 (2016).10.1021/acs.bioconjchem.6b00437 ↗
13. Nel, A., Ruoslahti, E. & Meng, H. New insights into ‘permeability’ as in the enhanced permeability and retention effect of cancer nanotherapeutics. ACS Nano 11, 9567–9569 (2017).10.1021/acsnano.7b07214 ↗
14. Huynh, E. & Zheng, G. Cancer nanomedicine: addressing the dark side of the enhanced permeability and retention effect. Nanomedicine 10, 1993–1995 (2015).10.2217/nnm.15.86 ↗
15. Nakamura, H., Jun, F. & Maeda, H. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls. Expert Opin. Drug Deliv. 12, 53–64 (2015); erratum 12, 691 (2015).10.1517/17425247.2014.955011 ↗
16. Rosenblum, D., Joshi, N., Tao, W., Karp, J. M. & Peer, D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat. Commun. 9, 1410 (2018).
17. Chan, W. C. W. Nanomedicine 2.0. Acc. Chem. Res. 50, 627–632 (2017).10.1021/acs.accounts.6b00629 ↗
18. Nagy, J. A. et al. Permeability properties of tumor surrogate blood vessels induced by VEGF-A. Lab. Invest. 86, 767–780 (2006).10.1038/labinvest.3700436 ↗
19. Feng, D. et al. Reinterpretation of endothelial cell gaps induced by vasoactive mediators in guinea-pig, mouse and rat: many are transcellular pores. J. Physiol. 504, 747–761 (1997).10.1111/j.1469-7793.1997.747bd.x ↗
20. Feng, D. et al. Pathways of macromolecular extravasation across microvascular endothelium in response to VPF/VEGF and other vasoactive mediators. Microcirculation 6, 23–44 (1999).10.1080/713773925 ↗
21. Dvorak, H. F., Nagy, J. A., Dvorak, J. T. & Dvorak, A. M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol. 133, 95–109 (1988).
22. Feng, D., Nagy, J. A., Dvorak, H. F. & Dvorak, A. M. Ultrastructural studies define soluble macromolecular, particulate, and cellular transendothelial cell pathways in venules, lymphatic vessels, and tumor-associated microvessels in man and animals. Microsc. Res. Tech. 57, 289–326 (2002).10.1002/jemt.10087 ↗
23. Neal, C. R. & Michel, C. C. Transcellular openings through frog microvascular endothelium. Exp. Physiol. 82, 419–422 (1997).10.1113/expphysiol.1997.sp004037 ↗
24. Michel, C. C. & Neal, C. R. Openings through endothelial cells associated with increased microvascular permeability. Microcirculation 6, 45–54 (1999).10.1080/713773926 ↗
25. Syed, A. M. et al. Three-dimensional imaging of transparent tissues via metal nanoparticle labeling. J. Am. Chem. Soc. 139, 9961–9971 (2017).10.1021/jacs.7b04022 ↗
26. Sindhwani, S., Syed, A. M., Wilhelm, S. & Chan, W. C. W. Exploring passive clearing for 3D optical imaging of nanoparticles in intact tissues. Bioconjug. Chem. 28, 253–259 (2017).10.1021/acs.bioconjchem.6b00500 ↗
27. Sindhwani, S. et al. Three-dimensional optical mapping of nanoparticle distribution in intact tissues. ACS Nano 10, 5468–5478 (2016).10.1021/acsnano.6b01879 ↗
28. Ramanujan, S. et al. Diffusion and convection in collagen gels: implications for transport in the tumor interstitium. Biophys. J. 83, 1650–1660 (2002).10.1016/S0006-3495(02)73933-7 ↗
29. Sykes, E. A. et al. Tailoring nanoparticle designs to target cancer based on tumor pathophysiology. Proc. Natl Acad. Sci. USA 113, E1142–E1151 (2016).10.1073/pnas.1521265113 ↗
30. Schnitzer, J. E. gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis. Am. J. Physiol. Heart Circulatory Physiol. 262, H246–H254 (1992).10.1152/ajpheart.1992.262.1.H246 ↗
31. Schnitzer, J. E. in Whole Organ Approaches to Cellular Metabolism (eds Bassingthwaighte, J., Goresky, C. A., Linehan, J. H 31–69 (Springer, 1998).10.1007/978-1-4612-2184-5_2 ↗
32. Oh, P. et al. In vivo proteomic imaging analysis of caveolae reveals pumping system to penetrate solid tumors. Nat. Med. 20, 1062–1068 (2014).10.1038/nm.3623 ↗
33. Thurston, G. et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J. Clin. Invest. 101, 1401–1413 (1998).10.1172/JCI965 ↗
34. McDonald, D. M. Uptake of cationic liposomes by normal and angiogenic endothelial cells in vivo. Nat. Biotechnol. 17, 14–14 (1999).10.1038/70129 ↗
35. Tkachenko, E. et al. Caveolae, fenestrae and transendothelial channels retain PV1 on the surface of endothelial cells. PLoS ONE 7, e32655 (2012).10.1371/journal.pone.0032655 ↗
36. Stan, R. V., Tkachenko, E. & Niesman, I. R. PV1 Is a key structural component for the formation of the stomatal and fenestral diaphragms. Mol. Biol. Cell 15, 3615–3630 (2004).10.1091/mbc.e03-08-0593 ↗
37. Stan, R. V. et al. The diaphragms of fenestrated endothelia: gatekeepers of vascular permeability and blood composition. Dev. Cell 23, 1203–1218 (2012).10.1016/j.devcel.2012.11.003 ↗
38. Dai, Q. et al. Quantifying the ligand-coated nanoparticle delivery to cancer cells in solid tumors. ACS Nano 12, 8423–8435 (2018).10.1021/acsnano.8b03900 ↗
39. Qaddoumi, M. G. et al. Clathrin and caveolin-1 expression in primary pigmented rabbit conjunctival epithelial cells: role in PLGA nanoparticle endocytosis. Mol. Vis. 9, 559–568 (2003).
40. Voigt, J., Christensen, J. & Shastri, V. P. Differential uptake of nanoparticles by endothelial cells through polyelectrolytes with affinity for caveolae. Proc. Natl Acad. Sci. USA 111, 2942–2947 (2014).10.1073/pnas.1322356111 ↗
41. Ho, Y. T., Kamm, R. D. & Kah, J. C. Y. Influence of protein corona and caveolae-mediated endocytosis on nanoparticle uptake and transcytosis. Nanoscale 10, 12386–12397 (2018).10.1039/C8NR02393J ↗
42. Chauhan, V. P. et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat. Nanotechnol. 7, 383–388 (2012).10.1038/nnano.2012.45 ↗
43. Schubert, W. et al. Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin in vivo. J. Biol. Chem. 276, 48619–48622 (2001).10.1074/jbc.C100613200 ↗
44. Matsumoto, Y. et al. Vascular bursts enhance permeability of tumour blood vessels and improve nanoparticle delivery. Nat. Nanotechnol. 11, 533–538 (2016).10.1038/nnano.2015.342 ↗
45. Naumenko, V. A. et al. Extravasating neutrophils open vascular barrier and improve liposomes delivery to tumors. ACS Nano 13, 12599–12612 (2019).10.1021/acsnano.9b03848 ↗
46. Harney, A. S. et al. Real-time imaging reveals local, transient vascular permeability, and tumor cell intravasation stimulated by TIE2hi macrophage-derived VEGFA. Cancer Discov. 5, 932–943 (2015).10.1158/2159-8290.CD-15-0012 ↗
47. Perrault, S. D. & Chan, W. C. W. Synthesis and surface modification of highly monodispersed, spherical gold nanoparticles of 50-200 nm. J. Am. Chem. Soc. 131, 17042–17043 (2009).10.1021/ja907069u ↗
48. Frens, G. Controlled nucleation for the regulation of the particle size in monodisperse gold suspensions. Nat. Phys. Sci. 241, 20–22 (1973).10.1038/physci241020a0 ↗
49. Sykes, E. A., Chen, J., Zheng, G. & Chan, W. C. W. Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency. ACS Nano 8, 5696–5706 (2014).10.1021/nn500299p ↗
50. Nakasone, E. S. et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 21, 488–503 (2012).10.1016/j.ccr.2012.02.017 ↗
51. Egeblad, M. et al. Visualizing stromal cell dynamics in different tumor microenvironments by spinning disk confocal microscopy. Dis. Model. Mech. 1, 155–167 (2008). discussion 165.10.1242/dmm.000596 ↗
52. Chou, L. Y. T. & Chan, W. C. W. Fluorescence-tagged gold nanoparticles for rapidly characterizing the size-dependent biodistribution in tumor models. Adv. Healthc. Mater. 1, 714–721 (2012).10.1002/adhm.201200084 ↗
53. Tavares, A. J. et al. Effect of removing Kupffer cells on nanoparticle tumor delivery. Proc. Natl Acad. Sci. U. S. A. 114, E10871–E10880 (2017).10.1073/pnas.1713390114 ↗